Just got FDA approval for their CAR T cell therapy, which is a big deal for Autolus. Goldman Sachs upgraded them to buy, raising the price target to $7.6. I see potential for the stock to climb, especially with the CAR T market growing.

I believe that owning shares of AUTL is a solid investment, especially following the positive analyst ratings and the promising clinical data updates for jejich CAR-T therapy. The recent appointment of a seasoned CFO and regulatory approvals further bolster my confidence in the stock's upward momentum.